Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

Zhou, Hu; Zhou, Jianfeng; Wu, Depei; Ma, Likun; Du, Xin; Niu, Ting; Yang, Rei‐Cheng; Liu, Jing; Zhang, Na; Shi, Qin; Wang, Xiuli; Jing, Hongmei; Li, Junmin; Wang, Xiaotian; Cui, Zhongguang; Zhou, Zeping; Hou, Mingxiao; Shao, Zonghong; Jin, Jie; Li, Wenqian; Ren, Hanyun; Hu, Jianda; Shen, Jian; Liu, Li; Zeng, Yun; Zhou, Jinming; Liu, Xin; Shen, Yongchun; Ding, Kai; Taira, Tomohide; Cai, Huacong; Zhao, Yongqiang

doi:10.1016/j.rpth.2023.100192

Research and Practice in Thrombosis and Haemostasis

2023

DOI: 10.1016/j.rpth.2023.100192

|View full text |Cite

Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

Hu Zhou¹,

Jianfeng Zhou²,

Depei Wu³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China

Luo,

Cheng,

et al. 2024

IRDR

View full text Add to dashboard Cite

This study aimed to assess the cost-utility of romiplostim (ROMI) compared to eltrombopag (EPAG) as a second-line treatment for chronic primary immune thrombocytopenia (cITP) in Chinese adults. A decision tree-embedded Markov model with a lifetime horizon was used to estimate the qualityadjusted life years (QALYs) and costs for ROMI versus EPAG from the perspective of the Chinese health care system. The model was driven by platelet response with a 4-week cycle. Both QALYs and costs were discounted 5% per year. Clinical data comparing ROMI and EPAG were obtained by matching-adjusted indirect comparison (MAIC), utilizing individual patient data on ROMI and published Chinese Phase III trial data on EPAG. Costs were reported in 2022 US dollars and included drug acquisition costs, monitoring costs, bleeding-related costs, and costs associated with adverse events. Deterministic and probabilistic sensitivity analyses were performed. The CEA model indicated that treatment with ROMI resulted in an average of $4,344.4 higher costs for 0.004 QALYs. Oneway sensitivity analysis (OSA) indicated that the model was most sensitive to the high bleeding rate in response (Markov stage) for EPAG and ROMI. Probabilistic sensitivity analysis (PSA) indicated that ROMI was likely to be cost effective in 0.16% cases at a willingness-to-pay threshold of $12039.1 (China per capita GDP in 2022) per QALY. If the price of ROMI is either lower than or equal to that of EPAG, ROMI could likely be considered cost-effective as a second-line treatment for Chinese adults with cITP.

show abstract

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China

Luo,

Cheng,

et al. 2024

IRDR

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China

Cited by 1 publication

References 29 publications

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China

Cost-utility analysis of romiplostim for the treatment of chronic primary immune thrombocytopenia in China

Contact Info

Product

Resources

About